{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:05:55Z","timestamp":1787317555329,"version":"build-2736575974"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T00:00:00Z","timestamp":1710374400000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Alberta Kidney Disease Network"},{"name":"Interdisciplinary Chronic Disease Collaboration"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Prior studies suggest that sodium\u2013glucose cotransporter-2 inhibitors (SGLT2is) may decrease the incidence of atrial fibrillation (AF). However, it is unknown whether SGLT2i can attenuate the disease course of AF among patients with pre-existing AF and Type II diabetes mellitus (DM). In this study, our objective was to examine the association between SGLT2i prescription and arrhythmic outcomes among patients with DM and pre-existing AF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>We conducted a population-based cohort study of adults with DM and AF between 2014 and 2019. Using a prevalent new-user design, individuals prescribed SGLT2i were matched 1:1 to those prescribed dipeptidyl peptidase-4 inhibitors (DPP4is) based on time-conditional propensity scores. The primary endpoint was a composite of AF-related healthcare utilization (i.e. hospitalization, emergency department visits, electrical cardioversion, or catheter ablation). Secondary outcome measures included all-cause mortality, heart failure (HF) hospitalization, and ischaemic stroke or transient ischaemic attack (TIA). Cox proportional hazard models were used to examine the association of SGLT2i with the study endpoint. Among 2242 patients with DM and AF followed for an average of 3.0 years, the primary endpoint occurred in 8.7% (n = 97) of patients in the SGLT2i group vs. 10.0% (n = 112) of patients in the DPP4i group [adjusted hazard ratio 0.73 (95% confidence interval 0.55\u20130.96; P = 0.03)]. Sodium\u2013glucose cotransporter-2 inhibitors were associated with significant reductions in all-cause mortality and HF hospitalization, but there was no difference in the risk of ischaemic stroke\/TIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among patients with DM and pre-existing AF, SGLT2is are associated with decreased AF-related health resource utilization and improved arrhythmic outcomes compared with DPP4is.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/europace\/euae054","type":"journal-article","created":{"date-parts":[[2024,3,14]],"date-time":"2024-03-14T15:25:16Z","timestamp":1710429916000},"source":"Crossref","is-referenced-by-count":22,"title":["Association between sodium\u2013glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation"],"prefix":"10.1093","volume":"26","author":[{"given":"Akash","family":"Fichadiya","sequence":"first","affiliation":[{"name":"Libin Cardiovascular Institute, Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary , 3330 Hospital Drive NW, T2N 4N1, Calgary, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1327-310X","authenticated-orcid":false,"given":"Amity","family":"Quinn","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"},{"name":"O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5189-8488","authenticated-orcid":false,"given":"Flora","family":"Au","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0733-3556","authenticated-orcid":false,"given":"Dennis","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta , 13-103 Clinical Sciences Building, 11350 - 83 Avenue NW, T6G 2G3 Edmonton, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9923-7902","authenticated-orcid":false,"given":"Darren","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alberta , 13-103 Clinical Sciences Building, 11350 - 83 Avenue NW, T6G 2G3 Edmonton, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3958-7561","authenticated-orcid":false,"given":"Paul","family":"Ronksley","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"},{"name":"O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8188-7616","authenticated-orcid":false,"given":"Reed","family":"Beall","sequence":"additional","affiliation":[{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"},{"name":"O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-3630","authenticated-orcid":false,"given":"David J T","family":"Campbell","sequence":"additional","affiliation":[{"name":"Libin Cardiovascular Institute, Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary , 3330 Hospital Drive NW, T2N 4N1, Calgary, AB , Canada"},{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"},{"name":"O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"},{"name":"Department of Medicine, Cumming School of Medicine, University of Calgary , 3330 Hospital Drive NW, T2N 4N1 Calgary, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B","family":"Wilton","sequence":"additional","affiliation":[{"name":"Libin Cardiovascular Institute, Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary , 3330 Hospital Drive NW, T2N 4N1, Calgary, AB , Canada"},{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"},{"name":"Department of Medicine, Cumming School of Medicine, University of Calgary , 3330 Hospital Drive NW, T2N 4N1 Calgary, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3539-7485","authenticated-orcid":false,"given":"Derek S","family":"Chew","sequence":"additional","affiliation":[{"name":"Libin Cardiovascular Institute, Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary , 3330 Hospital Drive NW, T2N 4N1, Calgary, AB , Canada"},{"name":"Department of Community Health Sciences, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"},{"name":"O\u2019Brien Institute for Public Health, Cumming School of Medicine, University of Calgary , 3280 Hospital Drive NW, T2N 4Z6 Calgary, AB , Canada"},{"name":"Department of Medicine, Cumming School of Medicine, University of Calgary , 3330 Hospital Drive NW, T2N 4N1 Calgary, AB , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,3,14]]},"reference":[{"key":"2024032716192572100_euae054-B1","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.tcm.2017.01.009","article-title":"The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors","volume":"27","author":"Secrest","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"2024032716192572100_euae054-B2","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2024032716192572100_euae054-B3","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"key":"2024032716192572100_euae054-B4","doi-asserted-by":"crossref","first-page":"e022222","DOI":"10.1161\/JAHA.121.022222","article-title":"Sodium-glucose co-transporter inhibitors and atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials","volume":"10","author":"Pandey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2024032716192572100_euae054-B5","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3389\/fphys.2018.01575","article-title":"Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients","volume":"9","author":"Uthman","year":"2018","journal-title":"Front Physiol"},{"key":"2024032716192572100_euae054-B6","author":"Statistics Canada"},{"key":"2024032716192572100_euae054-B7","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/pds.4107","article-title":"Prevalent new-user cohort designs for comparative drug effect studies by time-conditional propensity scores","volume":"26","author":"Suissa","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2024032716192572100_euae054-B8","author":"Government of Alberta"},{"key":"2024032716192572100_euae054-B9","author":"Government of Alberta"},{"key":"2024032716192572100_euae054-B10","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-2369-10-30","article-title":"Overview of the Alberta kidney disease network","volume":"10","author":"Hemmelgarn","year":"2009","journal-title":"BMC Nephrol"},{"key":"2024032716192572100_euae054-B11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12911-015-0155-5","article-title":"Methods for identifying 30 chronic conditions: application to administrative data","volume":"15","author":"Tonelli","year":"2015","journal-title":"BMC Med Inform Decis Mak"},{"key":"2024032716192572100_euae054-B12","doi-asserted-by":"crossref","first-page":"e001224","DOI":"10.1136\/bmjdrc-2020-001224","article-title":"Validation of a type 1 diabetes algorithm using electronic medical records and administrative healthcare data to study the population incidence and prevalence of type 1 diabetes in Ontario, Canada","volume":"8","author":"Weisman","year":"2020","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2024032716192572100_euae054-B13","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s40471-018-0155-y","article-title":"The importance and implications of comparator selection in pharmacoepidemiologic research","volume":"5","author":"D\u2019Arcy","year":"2018","journal-title":"Curr Epidemiol Rep"},{"key":"2024032716192572100_euae054-B14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green","year":"2015","journal-title":"N Engl J Med"},{"key":"2024032716192572100_euae054-B15","doi-asserted-by":"crossref","first-page":"585","DOI":"10.4330\/wjc.v13.i10.585","article-title":"Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"13","author":"Patoulias","year":"2021","journal-title":"World J Cardiol"},{"key":"2024032716192572100_euae054-B16","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"2024032716192572100_euae054-B17","doi-asserted-by":"crossref","first-page":"417","DOI":"10.7326\/M20-0289","article-title":"Sodium-glucose cotransporter-2 inhibitors and the risk for diabetic ketoacidosis: a multicenter cohort study","volume":"173","author":"Douros","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024032716192572100_euae054-B18","doi-asserted-by":"crossref","first-page":"m3342","DOI":"10.1136\/bmj.m3342","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study","volume":"370","author":"Filion","year":"2020","journal-title":"BMJ"},{"key":"2024032716192572100_euae054-B19","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1161\/HYPERTENSIONAHA.109.139279","article-title":"Validation of a case definition to define hypertension using administrative data","volume":"54","author":"Quan","year":"2009","journal-title":"Hypertension"},{"key":"2024032716192572100_euae054-B20","first-page":"85","article-title":"A comparison of individual and area-based socio-economic data for monitoring social inequalities in health","volume":"20","author":"Pampalon","year":"2009","journal-title":"Health Rep"},{"key":"2024032716192572100_euae054-B21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.24095\/hpcdp.29.4.05","article-title":"A deprivation index for health planning in Canada","volume":"29","author":"Pampalon","year":"2009","journal-title":"Chronic Dis Can"},{"key":"2024032716192572100_euae054-B22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.24095\/hpcdp.34.1.03","article-title":"Validation of a deprivation index for public health: a complex exercise illustrated by the Quebec index","volume":"34","author":"Pampalon","year":"2014","journal-title":"Chronic Dis Inj Can"},{"key":"2024032716192572100_euae054-B23","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1002\/sim.7501","article-title":"Practical recommendations for reporting Fine-Gray model analyses for competing risk data","volume":"36","author":"Austin","year":"2017","journal-title":"Stat Med"},{"key":"2024032716192572100_euae054-B24","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/01621459.2000.10474233","article-title":"Combining propensity score matching with additional adjustments for prognostic covariates","volume":"95","author":"Donald","year":"2000","journal-title":"J Am Stat Assoc"},{"key":"2024032716192572100_euae054-B25","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Jason","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"2024032716192572100_euae054-B26","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox\u2019s regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"key":"2024032716192572100_euae054-B27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/biomet\/68.2.373","article-title":"On the regression analysis of multivariate failure time data","volume":"68","author":"Prentice","year":"1981","journal-title":"Biometrika"},{"key":"2024032716192572100_euae054-B28","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/ije\/dyu222","article-title":"Modelling recurrent events: a tutorial for analysis in epidemiology","volume":"44","author":"Amorim","year":"2014","journal-title":"Int J Epidemiol"},{"key":"2024032716192572100_euae054-B29","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12933-022-01549-x","article-title":"The risk of incident atrial fibrillation in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors: a nationwide cohort study","volume":"21","author":"Chan","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"2024032716192572100_euae054-B30","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10557-022-07319-x","article-title":"Comparison of sodium-glucose cotransporter-2 inhibitor and dipeptidyl peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong","volume":"37","author":"Lee","year":"2023","journal-title":"Cardiovasc Drugs Ther"},{"key":"2024032716192572100_euae054-B31","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1016\/j.jacc.2018.03.009","article-title":"Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study","volume":"71","author":"Kosiborod","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2024032716192572100_euae054-B32","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12933-021-01243-4","article-title":"SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system","volume":"20","author":"Bonora","year":"2021","journal-title":"Cardiovasc Diabetol"},{"key":"2024032716192572100_euae054-B33","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacep.2022.08.004","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation","volume":"8","author":"Kishima","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"2024032716192572100_euae054-B34","doi-asserted-by":"crossref","first-page":"7976","DOI":"10.3390\/ijms22157976","article-title":"Cardioprotection by SGLT2 inhibitors-does it all come down to Na(+)?","volume":"22","author":"Trum","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2024032716192572100_euae054-B35","doi-asserted-by":"crossref","first-page":"e002183","DOI":"10.1161\/JAHA.115.002183","article-title":"Intracellular Na+ concentration ([Na+]i) is elevated in diabetic hearts due to enhanced Na+-glucose cotransport","volume":"4","author":"Lambert","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2024032716192572100_euae054-B36","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"2024032716192572100_euae054-B37","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1161\/CIRCULATIONAHA.122.057364","article-title":"Empagliflozin inhibits cardiac late sodium current by Ca\/calmodulin-dependent kinase II","volume":"146","author":"Mustroph","year":"2022","journal-title":"Circulation"},{"key":"2024032716192572100_euae054-B38","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1002\/ehf2.13024","article-title":"Empagliflozin inhibits Na(+)\/H(+) exchanger activity in human atrial cardiomyocytes","volume":"7","author":"Trum","year":"2020","journal-title":"ESC Heart Fail"},{"key":"2024032716192572100_euae054-B39","doi-asserted-by":"crossref","first-page":"1011429","DOI":"10.3389\/fcvm.2022.1011429","article-title":"Benefits of SGLT2 inhibitors in arrhythmias","volume":"9","author":"Gao","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2024032716192572100_euae054-B40","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cjca.2019.08.033","article-title":"Direct effects of empagliflozin on extracellular matrix remodelling in human cardiac myofibroblasts: novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"Can J Cardiol"},{"key":"2024032716192572100_euae054-B41","doi-asserted-by":"crossref","first-page":"e015176","DOI":"10.1161\/CIRCIMAGING.122.015176","article-title":"Empagliflozin improves left atrial strain in patients with type 2 diabetes: data from a randomized, placebo-controlled study","volume":"16","author":"Thiele","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"2024032716192572100_euae054-B42","doi-asserted-by":"crossref","first-page":"e0280359","DOI":"10.1371\/journal.pone.0280359","article-title":"Protocol of BEYOND trial: clinical benefit of sodium-glucose cotransporter-2 (SGLT-2) inhibitors in rhythm control of atrial fibrillation in patients with diabetes mellitus","volume":"18","author":"Lee","year":"2023","journal-title":"PLoS One"},{"key":"2024032716192572100_euae054-B43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels","volume":"183","author":"D'Andrea","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2024032716192572100_euae054-B44","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cjca.2020.04.026","article-title":"Temporal trends in population rates of incident atrial fibrillation and atrial flutter hospitalizations, stroke risk, and mortality show decline in hospitalizations","volume":"37","author":"Sandhu","year":"2021","journal-title":"Can J Cardiol"},{"key":"2024032716192572100_euae054-B45","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.hroo.2021.11.012","article-title":"Diagnosis-to-ablation time predicts recurrent atrial fibrillation and rehospitalization following catheter ablation","volume":"3","author":"Chew","year":"2022","journal-title":"Heart Rhythm O2"},{"key":"2024032716192572100_euae054-B46","doi-asserted-by":"crossref","first-page":"e009294","DOI":"10.1161\/JAHA.118.009294","article-title":"Causes and predictors of readmission in patients with atrial fibrillation undergoing catheter ablation: a national population-based cohort study","volume":"7","author":"Arora","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2024032716192572100_euae054-B47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/eurheartj\/ehx466","article-title":"Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study","volume":"39","author":"Pallisgaard","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/26\/3\/euae054\/57099381\/euae054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/26\/3\/euae054\/57099381\/euae054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T15:50:18Z","timestamp":1711554618000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euae054\/7628652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,1]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euae054","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,3]]},"published":{"date-parts":[[2024,3,1]]},"article-number":"euae054"}}